Maxicuma

Maxicuma is a patented, highly bioavailable turmeric (Curcuma longa) extract standardized to contain at least 40% curcuminoids, with curcumin as the primary active constituent. Developed by Ennature Biopharma (a division of India Glycols), Maxicuma is formulated using the proprietary LIMAN™ (lecithin-based liposomal microencapsulation) technology, also marketed as BioRelay™ true water solution. This technology combines lecithin encapsulation with submicron particle size reduction to convert hydrophobic curcumin into a cold-water-dispersible matrix, protecting the curcuminoids from gastrointestinal and enzymatic degradation. This formulation delivers approximately 172-fold more free curcumin in human plasma compared to standard 95% micronized curcumin. Maxicuma is marketed as a nutraceutical ingredient for joint health, mobility, and physical performance, with clinical evidence supporting its efficacy in reducing joint pain and stiffness in patients with mild to moderate osteoarthritis.